ORKA (Oruka Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on ORKA (Oruka Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

ORKA

Oruka Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA)
Nov 15, 2025
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 12, 2025
Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know
Oct 29, 2025
Oruka Therapeutics to Present at Multiple November Investor Conferences
Oct 29, 2025
Oruka Therapeutics Says ORKA-001 Interim Early-Stage Data Supports Extended Dosing Intervals; Plans $180 Million Private Placement
Sep 17, 2025
Oruka Therapeutics Announces $180 Million Private Placement
Sep 17, 2025
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Sep 17, 2025
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 11, 2025
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
Jul 21, 2025
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
Jul 1, 2025
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
May 27, 2025
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
May 21, 2025
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
May 20, 2025

Reviews